Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

iOpeners

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

Dan Ignaszewski explains how the national advocacy campaign aims to unite patients, researchers, and clinicians to protect NEI’s independence and ensure vision research funding.

Q&A: AEVR's executive director on #SeeWhatMatters and safeguarding the National Eye Institute

Annexin Pharmaceuticals initiates a Phase 2a study for ANXV in diabetic retinopathy  to explore new treatment options and improve patient outcomes.

UK MHRA approves phase 2a study for ANXV for diabetic retinopathy

The company previously provided an update in April 2025 stating its intention to lay off approximately 65% of the company after the COAST trial failed to meet its primary end point.

Opthea parts with CEO, lays off over 80% of company

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and, in some cases, blindness.

FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Advanced Solutions for Retinal Vascular Diseases: Achieving Superior Outcomes with Durable Treatments

Video Series

Treating a DME Patient Lost to Follow-Up with a Highly Durable Agent

Videos

A panel expert retina specialists present challengingcases of neovascular AMD and DME and have a comprehensive discussion on the benefits of novel durable treatments.

Adiel Smith, MD, FASRS, presents the case of a patient with neovascular age-related macular degeneration (nAMD) with treatment-resistant pigment epithelium detachment, and the panel offers clinical insights on treatment decisions.

A Case of Neovascular AMD With Treatment-Resistant Pigment Epithelium Detachment

Jaclyn Kovach, MD, FASRS, presents the case of a patient with neovascular AMD with persistent subretinal fluid, and members of the panel share their experiences treating similar patients.

A Case of Neovascular AMD with Persistent Subretinal Fluid

Katherine Talcott, MD, presents the case of a patient with diabetic macular edema, and the rest of the panel share their clinical experiences and discuss factors that inform the utilization of more durable agents.

Greg Budoff, MD, presents the case of a patient with diabetic macular edema who achieved extended treatment interval, and the panel discusses treatment considerations, including the role of PRN regimens.

A Case of a DME Patient Achieving Extended Treatment Interval with New Therapy

Expert retina speclialists discuss evolving treatment paradigms and the role of intravitreal steroids and macular laser for treating diabetic macular edema.

Evolving Role of Steroids and Laser In DME

The panel concludes its discussion with thoughts on the profound impact durable treatments have on the quality of life of patients with retinal diseases.

Impact Of Durable Agents on Treatment Burden and Quality of Life in Retinal Diseases

Treating a DME Patient Lost to Follow-Up with a Highly Durable Agent

EP: 1.A Case of Neovascular AMD With Treatment-Resistant Pigment Epithelium Detachment

EP: 2.A Case of Neovascular AMD with Persistent Subretinal Fluid

EP: 3.Treating a DME Patient Lost to Follow-Up with a Highly Durable Agent

EP: 4.A Case of a DME Patient Achieving Extended Treatment Interval with New Therapy

EP: 5.Evolving Role of Steroids and Laser In DME

EP: 6.Impact Of Durable Agents on Treatment Burden and Quality of Life in Retinal Diseases

Newsletter